Search results for " predictive"

showing 10 items of 163 documents

THE INTERPRETAZION OF DIAGNOSTIC TEST: A PRIMER OF ALLERGIST. PRICIPLES OF EVIDENCE BASED MEDICINE TO OBTAIN A PRECISE DIAGNOSIS

2008

Negative predictive value (NPV)Lkelihood ratio negative (LR-)SensitivitySettore MED/09 - Medicina InternaLkelihood ratio positive (LR+)SpecificityEosinophilAsthmaPositive predictive value (PPV)Rhinitis
researchProduct

Predictive Intelligent Fuzzy Control for Cooperative Motion of Two Nonholonomic Wheeled Cars

2007

In this paper a problem of intelligent cooperative motion control of two wheeled nonholonomic cars (target and follower) is considered. Once a target car converges to a fixed state (position and orientation), a follower car coming from different position and orientation, converges to the state above, without excessive delay between the known arrival time of the target car and the arrival time of the follower. In this sense we present a new predictive fuzzy control system. A Kalman's filter and an odometric model are used to predict the future position and orientation of the target car. The prediction above is employed to plane a circular nonholonomic reference motion for the follower car. A…

Nonholonomic systemEngineeringbusiness.industryControl engineeringFuzzy control systemKalman filterMotion controlFuzzy logicModel predictive controlSettore ING-INF/04 - AutomaticaControl theoryPosition (vector)Intelligent control Fuzzy control Motion control Kinematics Velocity control Intelligent transportation systems Delay effects Vehicle dynamics State estimation Error correctionbusinessIntelligent control2007 IEEE Intelligent Transportation Systems Conference
researchProduct

Linear parameter estimation and predictive constrained control of wiener/hammerstein systems

2003

Abstract A new, analytical, orthonormal basis functions (OBF)-based design methodology for adaptive predictive constrained control of open-loop stable, possibly nonminimum phase, time-varying Wiener and Hammerstein systems is presented. A linear adaptive least-squares parameter estimation algorithm is applied both to a nonlinear static part and a linear dynamic, OBF-modeled factor of the Wiener/Hammerstein system. A notion of inverse systems is crucial for linear estimation of both Wiener and Hammerstein systems, with in verses of the nonlinear or linear parts respectively involved. The adaptive estimator is coupled with a simple but robust, predictive control strategy called Extended Horiz…

Nonlinear systemModel predictive controlAdaptive controlEstimation theoryControl theoryAdaptive systemAdaptive estimatorInverseNonlinear controlMathematicsIFAC Proceedings Volumes
researchProduct

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differ…

2012

The 1st St. Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel clearly differentiated treatment and staging recommendations for the various gastroesophageal cancers. For locally advanced gastric cancer (>= PT3N+), the preferred treatment modality was pre- and postoperative chemotherapy. The majority of panel members would also treat T2N+ or even T2N0 tumours with a similar approach mainly because pretherapeutic staging was considered highly unreliable. It was agreed that adenocarcinoma of the gastroesophageal junction (AEG) is classified best according to Siewert et al. Preoperative radiochemotherapy (RCT) is the preferred treatment for AEG type I and II tumours. For AEG type…

OncologyCancer Researchmedicine.medical_specialtyEsophageal Neoplasmspathology/surgery/therapymedicine.medical_treatmentAdenocarcinoma; pathology/surgery/therapy Carcinoma; Squamous Cell; pathology/surgery/therapy Chemoradiotherapy; Adjuvant Chemotherapy; Adjuvant Early Detection of Cancer Esophageal Neoplasms; pathology/surgery/therapy Esophagectomy Esophagogastric Junction; pathology/surgery Gastrectomy Humans Neoadjuvant Therapy Neoplasm Staging Predictive Value of Tests Stomach Neoplasms; pathology/surgery/therapy Treatment OutcomePredictive Value of TestAdenocarcinomaSDG 3 - Good Health and Well-beingPredictive Value of TestsStomach NeoplasmsGastrectomyStomach NeoplasmInternal medicineCarcinomamedicineHumansChemotherapyGastrointestinal cancerEsophageal NeoplasmLymph nodeAdjuvantEarly Detection of CancerNeoadjuvant therapyNeoplasm Stagingpathology/surgerybusiness.industryCarcinomaCancerChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseNeoadjuvant TherapyEsophagectomyTreatment Outcomemedicine.anatomical_structureSquamous CellOncologyChemotherapy AdjuvantEsophagectomyCarcinoma Squamous CellAdenocarcinomaEsophagogastric JunctionbusinessChemoradiotherapyHuman
researchProduct

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer

2016

International audience; Background: To determine whether dose/volume specific endpoints (DVSE) or Area under the rectal DVH curve (rAUC) better predict acute gastrointestinal (GI) toxicity in prostate cancer patients treated with IMRT in the era of daily image guidance (IG-IMRT). Methods: A set of DVSE was recorded from V25 to V75 (increments of 5Gy) (both in % and in cc) for 180 men. The rAUC was calculated for doses ranging between 25Gy and 50Gy (rAUC(25-50)). Univariate and multivariate logistic regressions were performed to determine the relationship between DVSE or rAUC(25-50) and the appearance of any acute GI toxicity. Results: The rates of acute grade 1 (G1), G2 and G3 GI toxicities…

OncologyMale[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterology030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineProstate cancer0302 clinical medicineProstateLarge intestineConformal Radiation-Therapy[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overGastrointestinal tractProstate cancerRadiotherapy DosageMiddle Aged3. Good healthmedicine.anatomical_structureImpactOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisArea Under CurveToxicityImage Guidancemedicine.medical_specialtyRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesInternal medicinemedicineBiochemical ControlHumansRadiology Nuclear Medicine and imagingRadiation InjuriesAgedRadiotherapybusiness.industryResearchRectumProstatic Neoplasmsmedicine.diseaseRadiation therapyAcute rectal toxicity predictive factorLogistic ModelsRadiotherapy Intensity-ModulatedbusinessAbsolute volumeRadiation Oncology (London, England)
researchProduct

Monoclonal antibodies in gastrointestinal cancers

2013

Introduction: Among gastrointestinal cancers, colorectal and gastric neoplasms are the most frequent. The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those malignancies. Areas covered: This review highlights the main biological processes implicated in gastrointestinal cancer development and progression, such as angiogenesis and epidermal growth factor receptor (EGFR) signaling pathway. On these bases, anti-EGFR and anti-vascular endothelial growth factor (VEGF) monoclonal antibodies in colorectal and gastric cancer are discussed. Data about further monoclonal antibodies in development are also reported. Expert opinion: The use of monoclo…

OncologyVascular Endothelial Growth Factor AColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryPredictive Value of TestAntineoplastic AgentVascular Endothelial Growth Factor A; Animals; Antineoplastic Agents; Receptor Epidermal Growth Factor; Humans; Molecular Targeted Therapy; Predictive Value of Tests; Patient Selection; Antibodies Monoclonal; Genetic Testing; Individualized Medicine; Gastrointestinal Neoplasms; Tumor Markers Biological; Signal TransductionGastricDrug DiscoveryMonoclonalEpidermal growth factor receptorMolecular Targeted TherapyPrecision MedicineTumor MarkersColorectalCancerGastrointestinal NeoplasmsbiologyAntibody; Cancer; Colorectal; Gastric; Monoclonal; Animals; Antibodies Monoclonal; Antineoplastic Agents; Gastrointestinal Neoplasms; Genetic Testing; Humans; Individualized Medicine; Molecular Targeted Therapy; Patient Selection; Predictive Value of Tests; Receptor Epidermal Growth Factor; Signal Transduction; Tumor Markers Biological; Vascular Endothelial Growth Factor A; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalIndividualized MedicineErbB ReceptorsTumor Markers BiologicalGastrointestinal NeoplasmMonoclonalGastric NeoplasmHumanReceptorSignal Transductionmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsMonoclonal antibodyAntibodiesPredictive Value of TestsInternal medicinemedicineBiomarkers TumorAnimalsHumansGastrointestinal cancerGenetic TestingAntibodyPharmacologyEpidermal Growth Factorbusiness.industryAnimalDrug Discovery3003 Pharmaceutical SciencePatient SelectionCancermedicine.diseaseBiologicalbiology.proteinReceptor Epidermal Growth Factorbusiness
researchProduct

Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis

2017

Worldwide, colorectal cancer (CRC) screening programs have significantly increased the detection of submucosal (pT1) adenocarcinoma. Completion surgery may be indicated after endoscopic excision of these potentially metastasizing early cancers. However, the postsurgical prevalence of nodal implants does not exceed 15%, leading to questions concerning the clinical appropriateness of any post–endoscopy surgery. Eastern scientific societies (Japanese Society for Cancer of the Colon-Rectum, in particular) include tumor budding (TB), defined as the presence of isolated single cancer cells or clusters of fewer than 5 cancer cells at the tumor invasive front, among the variables that must be inclu…

Oncologymedicine.medical_specialtyColorectal cancerBiopsyTumor buddingAdenocarcinomaRisk AssessmentPathology and Forensic MedicineColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor buddingColorectal cancer; Lymph node metastasis; Meta-analysis; Sprouting; Tumor budding; Adenocarcinoma; Biopsy; Colorectal Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; Cell MovementLymph node metastasi03 medical and health sciences0302 clinical medicineTumor buddingPredictive Value of TestsRisk FactorsCell MovementTumor budding.Internal medicineBiopsymedicineOdds RatioHumansMeta-analysiNeoplasm InvasivenessRisk factorNeoplasm StagingLymph node metastasismedicine.diagnostic_testbusiness.industryCancerOdds ratiomedicine.diseaseColorectal cancerSurgeryMeta-analysis030220 oncology & carcinogenesisPredictive value of testsLymphatic MetastasisAdenocarcinoma030211 gastroenterology & hepatologyLymph NodesbusinessColorectal NeoplasmsSprouting
researchProduct

Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients

2011

Fluoropyrimidines and oxaliplatin continued to be the mainstay of therapeutic regimens in the treatment of colorectal cancer (CRC). For this reason, pharmacokinetic and metabolism of these drugs were analyzed and the identification of accurate and validated predictive, prognostic and toxicity markers became necessary to develop an effective therapy adapted to the patient's molecular profile, while minimizing life-threatening toxicities. In this review, we discuss literature data, defining predictive and prognostic markers actually identified in the treatment of CRC. We analyzed predictive markers of fluoropyrimidines effectiveness, principally for 5-Fluorouracil (5-FU) and also for oral flu…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia Medica5-FluorouracilPredictive markerClinical BiochemistryAntineoplastic AgentsPharmacologyThymidylate synthaseXRCC1Internal medicinemedicineDihydropyrimidine dehydrogenaseBiomarkers TumorHumans5-Fluorouracil; Dihydropyrimidine dehydrogenase; Glutathione S-transferase; Nucleotide excision repair; Oxaliplatin; Predictive marker; Thymidylate Synthase; Toxicity marker; Pharmacology; Clinical BiochemistryPharmacologyPredictive markerbiologyMicrosatellite instabilityThymidylate Synthasemedicine.diseaseToxicity markerOxaliplatinGlutathione S-transferaseOxaliplatinNucleotide excision repairPyrimidinesbiology.proteinERCC1Colorectal NeoplasmsDihydropyrimidine dehydrogenasemedicine.drug
researchProduct